ClinicalTrials.gg

Program

tebipenem

Also written as “TBPM-PI-HBr”, “TBP-PI-HBr” and “Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)”.

Its studies are mostly in Urinary Tract Infections · Pyelonephritis · Renal Insufficiency, led by Spero Therapeutics.

Furthest: phase 3, since Dec 22, 201812 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Spero Therapeutics120 open or runningphase 3since Dec 22, 2018Oct 19, 2017none ahead

Also a collaborator on its studies: GlaxoSmithKline, iqvia-pty-ltd, clinartis, covance, celerion and cpr-pharma-services-pty-ltd-australia.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2017First study: phase 1 study in Healthy VolunteersFirst studyNCT03395249 · 124 enrolled · Australia
  2. Dec 22, 2018Phase 3 study in Complicated Urinary Tract InfectionNCT03788967 · 1,372 enrolled · United States, Bulgaria, Czechia and more
  3. Nov 14, 2019Phase 1 study in Renal InsufficiencyNCT04178577 · 39 enrolled · United States
  4. Jan 16, 2020Phase 1 study in TQT StudyNCT04238195 · 24 enrolled · United States
  5. Mar 16, 2020Phase 1 study in Healthy VolunteersNCT04376554 · 30 enrolled · Sweden
  6. Apr 9, 2020Phase 1 study in Healthy VolunteersNCT04368585 · 20 enrolled · United States
  7. Jun 4, 2020Phase 1 study in Healthy VolunteersNCT04421885 · 36 enrolled · United States
  8. Sep 17, 2020Phase 1 study in Healthy VolunteersNCT04625855 · 8 enrolled · United States
  9. Jan 4, 2021Phase 1 study in Healthy VolunteersNCT04710407 · 30 enrolled · United States
  10. May 3, 2023Phase 1 study in Healthy VolunteersNCT05856747 · 20 enrolled · United States
  11. Sep 22, 2023Phase 3 study in Urinary Tract InfectionsNCT06059846 · 1,690 enrolled · United States, Argentina, Bosnia and Herzegovina and more
  12. Dec 6, 2024Phase 1 study in Healthy ParticipantsNCT06727136 · 39 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06727136Healthy Participants · United States1CompletedApr 22, 202539
NCT06059846Urinary Tract Infections · United States, Argentina, Bosnia and Herzegovina and more3CompletedJan 27, 20251,690
NCT05856747Healthy Volunteers · United States1CompletedJun 1, 202320
NCT04710407Healthy Volunteers · United States1CompletedMar 10, 202130
NCT04625855Healthy Volunteers · United States1CompletedOct 16, 20208
NCT04421885Healthy Volunteers · United States1CompletedJul 11, 202036
NCT04368585Healthy Volunteers · United States1CompletedAug 8, 202020
NCT04376554Healthy Volunteers · Sweden1CompletedApr 6, 202130
NCT04238195TQT Study · United States1CompletedFeb 26, 202024
NCT04178577Renal Insufficiency · United States1CompletedSep 6, 202039
NCT03788967Complicated Urinary Tract Infection · United States, Bulgaria, Czechia and more3CompletedMay 20, 20201,372
NCT03395249Healthy Volunteers · Australia1CompletedAug 2, 2018124

How it is read

Names in the registry

  • “TBPM-PI-HBr”, 4 entries
  • “TBP-PI-HBr”, 3 entries
  • “Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)”, 2 entries
  • “Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference”, 1 entry
  • “Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.